Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CLDX
Previous Symbol
CUSIP15117B10
Phone908-200-7500
Debt
Debt-to-Equity RatioN/A
Current Ratio6.59
Quick Ratio6.59
Price-To-Earnings
Trailing P/E Ratio-0.41
Forward P/E Ratio-0.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.74 million
Price / Sales4.47
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book0.45
Profitability
EPS (Most Recent Fiscal Year)($0.80)
Net Income$-93,030,000.00
Net Margins-1,296.96%
Return on Equity-51.88%
Return on Assets-38.08%
Miscellaneous
Employees192
Outstanding Shares172,470,000
Market Cap$57.95 million
OptionableOptionable
Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions
What is Celldex Therapeutics' stock symbol?
Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."
How were Celldex Therapeutics' earnings last quarter?
Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.03. The biopharmaceutical company earned $2.76 million during the quarter, compared to analysts' expectations of $2.70 million. Celldex Therapeutics had a negative net margin of 1,296.96% and a negative return on equity of 51.88%. View Celldex Therapeutics' Earnings History.
When is Celldex Therapeutics' next earnings date?
What price target have analysts set for CLDX?
6 analysts have issued twelve-month target prices for Celldex Therapeutics' shares. Their predictions range from $2.00 to $10.00. On average, they anticipate Celldex Therapeutics' share price to reach $4.50 in the next twelve months. This suggests a possible upside of 1,263.6% from the stock's current price. View Analyst Price Targets for Celldex Therapeutics.
What is the consensus analysts' recommendation for Celldex Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Celldex Therapeutics.
What are Wall Street analysts saying about Celldex Therapeutics stock?
Here are some recent quotes from research analysts about Celldex Therapeutics stock:
- 1. Cowen Inc analysts commented, "We are pleased with Endo’s beat and raise quarter as the company continues to pivot itself into a more specialized company with foci on durable brands like Xiaflex, specialty injectables and a specialty generic base business. As such, the strength in the shares seen post earnings likely indicates that investors are pleased with management’s recent actions (as are we). At the same time we continue to view current debt levels, ongoing opioid litigation, and legal liabilities as significant overhangs on the name that could stunt momentum and remain HOLD rated on ENDP shares." (8/9/2018)
- 2. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline received a major setback with failure of its lead pipeline candidate, glembatumumab vedotin, in a breast cancer study. Following the failure, the company discontinued the development of the candidate across all indications. With no approved products, further pipeline setbacks will severely impact Celldex. The company is now focusing on other promising candidates in its pipeline including varlilumab. Meanwhile, the Kolltan acquisition added some interesting candidates to the company’s pipeline. However, Celldex depends entirely on product development, licensing agreements, contracts and grants for revenues. Shares of the company have significantly underperformed the industry so far this year. Loss estimates have widened ahead of the company’s Q2 earnings release. Celldex has a positive record of surprises in recent quarters." (7/17/2018)
- 3. Cantor Fitzgerald analysts commented, "Glemba is a Miss. The METRIC trial evaluating metastatic TNBC patients that overexpress gpNMB versus capecitibine did not achieve statistical significance, with glemba-treated patients experiencing PFS of 2.7 months versus 2.6 months for capecitibine, p=0.76. Additionally, significance was not achieved for key secondary endpoints of OR (overall response), DoR (Duration of Response) or OS (Overall Survival)." (4/17/2018)
Has Celldex Therapeutics been receiving favorable news coverage?
Headlines about CLDX stock have trended somewhat positive this week, according to InfoTrie. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Celldex Therapeutics earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Are investors shorting Celldex Therapeutics?
Celldex Therapeutics saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 2,916,242 shares, a decrease of 27.5% from the October 15th total of 4,021,311 shares. Based on an average daily volume of 2,387,889 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.8% of the company's shares are sold short. View Celldex Therapeutics' Current Options Chain.
Who are some of Celldex Therapeutics' key competitors?
Some companies that are related to Celldex Therapeutics include Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), ImmuCell (ICCC), Vermillion (VRML), Riot Blockchain (RIOT), Arca Biopharma (ABIO), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ), Akers Biosciences (AKER) and Palatin Technologies (PTN).
Who are Celldex Therapeutics' key executives?
Celldex Therapeutics' management team includes the folowing people:
- Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 56)
- Dr. Tibor Keler, Founder, Chief Scientific Officer & Exec. VP (Age 59)
- Mr. Sam Martin, Sr. VP, CFO, Sec. & Treasurer (Age 47)
- Ms. Elizabeth Crowley, Chief Product Devel. Officer & Sr. VP (Age 46)
- Dr. Richard M. Wright Ph.D., Chief Commercial Officer & Sr. VP (Age 54)
Who are Celldex Therapeutics' major shareholders?
Celldex Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (3.10%), BlackRock Inc. (2.34%), Dimensional Fund Advisors LP (2.14%) and GSA Capital Partners LLP (0.74%). Company insiders that own Celldex Therapeutics stock include James J Marino and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.
Which institutional investors are selling Celldex Therapeutics stock?
Which institutional investors are buying Celldex Therapeutics stock?
CLDX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP and BlackRock Inc.. Company insiders that have bought Celldex Therapeutics stock in the last two years include James J Marino and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.
How do I buy shares of Celldex Therapeutics?
Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celldex Therapeutics' stock price today?
One share of CLDX stock can currently be purchased for approximately $0.33.
How big of a company is Celldex Therapeutics?
Celldex Therapeutics has a market capitalization of $57.95 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-93,030,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Celldex Therapeutics employs 192 workers across the globe.
What is Celldex Therapeutics' official website?
How can I contact Celldex Therapeutics?
Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]
MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe CLDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
